Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-11-14
2006-11-14
Schwadron, Ronald B. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S178100, C424S182100, C424S183100, C424S189100, C424S193100, C424S192100, C424S196110, C424S199100, C424S236100, C530S324000, C530S403000, C530S826000, C514S012200
Reexamination Certificate
active
07135185
ABSTRACT:
Immunogenic compositions comprising an immunogenic polypeptide and a pharmaceutically acceptable vehicle are described. The immunogenic polypeptide comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8). The immunogenic polypeptide can be coupled to a pharmaceutically acceptable carrier, such as a diphtheria toxoid.
REFERENCES:
patent: 4341761 (1982-07-01), Ganfield
patent: 4399121 (1983-08-01), Albarella
patent: 4427783 (1984-01-01), Newman
patent: 4444887 (1984-04-01), Hoffmann
patent: 4466917 (1984-08-01), Nussenzweig
patent: 4472500 (1984-09-01), Milstein
patent: 4491632 (1985-01-01), Wands
patent: 4493890 (1985-01-01), Morris
patent: 4517304 (1985-05-01), Stott et al.
patent: 4629783 (1986-12-01), Cosand
patent: 4683195 (1987-07-01), Mullis
patent: 4683202 (1987-07-01), Mullis
patent: 4722840 (1988-02-01), Valenzuela
patent: 4816397 (1989-03-01), Boss
patent: 4816567 (1989-03-01), Cabilly
patent: 5308750 (1994-05-01), Mehta et al.
patent: 5574132 (1996-11-01), Lacroix
patent: 5728520 (1998-03-01), Weiner et al.
patent: 5747239 (1998-05-01), Wang et al.
patent: 5756312 (1998-05-01), Weiner et al.
patent: 5766845 (1998-06-01), Weiner et al.
patent: 5942234 (1999-08-01), Ralston
patent: 6146633 (2000-11-01), Stevens
patent: 0 116 201 (1984-08-01), None
patent: 0 120 551 (1984-10-01), None
patent: 0 164 556 (1985-12-01), None
patent: 0 259 149 (1988-03-01), None
patent: 0 360 088 (1990-03-01), None
patent: 0 388 232 (1990-09-01), None
patent: 0 468 527 (1992-01-01), None
patent: 0 725 824 (1996-08-01), None
patent: 0 759 937 (1997-03-01), None
patent: 89/04669 (1989-06-01), None
patent: 90/11089 (1990-10-01), None
patent: WO 90/11089 (1990-10-01), None
patent: 90/14436 (1990-11-01), None
patent: WO 90/14837 (1990-12-01), None
patent: 92/08734 (1992-05-01), None
patent: WO 92/08734 (1992-05-01), None
patent: WO 93/00365 (1993-01-01), None
patent: 93/04205 (1993-03-01), None
patent: WO 93/06126 (1993-04-01), None
patent: WO 93/16126 (1993-08-01), None
patent: WO 93/18054 (1993-09-01), None
Weiner et al., Proc. Natl. Acad., Sci. USA 89, 3468-3472 (1992). see entire article.
Rudinger, InPeptide Hormones, ed. J. A. Parsons, University Park Press, Baltimore, pp. 1-7, 1976.
Mariko et al., Vaccine, vol. 20, p. 3095-3103, 2002 (abstract therof).
Barrett, J.T., Basic immunology and its medical application, Second Edition, 1980, 14-17.
Berzofsky et al., Chapter 8, from : “Fundamental Immunology, Second Ed.” Ed. W.E. Paul, Raven Press Ltd., 1989, pp. 176, 177, 201, 202.
Botarelli, P. et al., “T-Lymphocyte Response to Hepatitis C Virus in Different Clinical Courses of Infection”, Gastroenterology, 1993, 104, 580-587.
Brennan, M. et al., “The foliclle cells are a major site of vitellogenin inDrosophilia melanogaster”, Dev. Biol., 1982, 89, 225-236.
Broach, R., “Construction of High Copy Yeast Vectors Using 2-.mu.m Circle Sequences,” Meth. Enz., 1983, 101, 307-325.
Chakrabarti et al., “Vaccinia Virus Expression Vector: Coexpression of .beta.- Galactosidase Provides Visual Screening of Recombinant Virus Plaques,” Mol. Cell Biol., 1985, 5(12), 3403-3409.
Choo et al., “Vaccination of chimpanzees against infection by the hepatitis C virus”, Proc. Natl. Acad. Sci. USA, 1994, 91, 1294-1298.
Choo, Q.L. et al., “Hepatitis C virus: The major causative agent of viral non-A, non-B hepatitis”, Br. Bull., 1990, 46(2), 423-441.
Choo, Q.L. et al., “Genetic organization and diversity of the hepatitis C virus”, Proc. Natl. Acad. Sci. USA, 1991, 88, 2451-2455.
Choo, Q.L. et al., “Hepatitis C virus is a distant relative of the flaviviruses and pestiviruses”, in Proceedings of the International Meeting on Non-A, Non-B Hepatitis, Shikata, T. et al. (eds.), Tokyo, Japan, Amsterdam: Elsevier, 1991, 47-52.
Choo, Q.L. et al., “Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome”, Science, 1989, 244, 359-362.
Choo, Q.L. et al., “Identification of the major, parenteral non-A, non-B hepatitis agent (hepatitis C virus) using a recombinant cDNA approach”, Seminars in Liver Disease, 1992, 12(3), 279-288.
Coffin et al. (eds.), RNA Tumor Viruses, 2nd Edition, Cold Spring Harbor Laboratory, New York, 1985, vol. 2, 17-73.
Cuypers, H.T. et al., “Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus”, J. Clin. Microbiol., 1992, 30(12), 3220-3224.
Cuypers, H.T.M. et al., “Analysis of genomic variability of hepatitis-C virus”, J. Hepatology, 1991, 13(Suppl. 4), S15-S19.
DeBoer et al., “The tac promoter: a functional hybrid derived from the trp and lac promoters,” Proc. Natl. Acad. Sci. USA, 1983, 80(1), 21-25.
Erickson, A.L. et al., “Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C”, J. Immunol., 1993, 151(8), 4189-4199.
Esquivel et al., “T Cell Recognition of Hepatitis C Virus in Patients with Chronic Hepatitis C,” Gastroenterology, vol. 104, No. 4, Part 2, Apr. 1993, one page.
Esumi et al., “In vivo and in vitro evidence that cross-reactive antibodies to C-terminus of hypervariable region 1 do not neutralilze heterologous hepatitis C virus,” Vaccine (2002), vol. 20, pp. 3095-3103.
Fahey et al., Clin. Exp. Immunol., (1992) 88:1-5.
Farci et al., “Prevention of Hepatitis C Virus Infection in Chimpanzees by Hyperimmune Serum Against the Hypervariable Region 1 of the Envelope 2 Protein,” PNAS 1996, 93(26):15394-9.
Fausto-Sterling, A. et al., “Analysis of a newly-isolated temperature-sensitive maternal effect mutation ofDrosophila melanogaster”, J. Exper. Zoo., 1976, 200, 199-209.
Fiers et al., “Complete nucleotide sequence of SV40 DNA,” Nature, 1978, 273, 113-120.
Goeddel et al., “Synthesis of human fibroblast interferon byE. coli,” Nucl. Acids Res., 1980, 8(18), 4057-4075.
Guntaka, R.V. et al., “Effect of 5-Methyllcytidine on virus production in avian sarcoma virus-infected chicken embryo cells”, Virology, 1979, 29(2), 475-482.
Guntaka, R.V. et al., “Effect of dibutyricyclic AMP on intracellular levels of avian sarcoma virus specific RNA”, Nature, 1978, 274, 274-276.
Hattori et al., “Cross-Reactivity of Anti-Hypervariable Region Antibody of HCV Infected Patients,” 4thInternat'l Meeting on Hepatitis C Virus and Related Viruses, Mar. 6-10, 1997, Kyoto, Japan, p. 119 and abstract p. 306.
Hess et al., “Cooperation of glycolytic enzymes,” J. Adv. Enzyme Reg., 1968, 7, 149-167.
Hijikata et al., 1991 Biochemical and Biophysical Research Communications 175(1):220-228.
Hitzeman et al., “Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique,” J. Biol. Chem., 1980, 255(24), 12073-12080.
Holland et al., “The primary structures of two yeast enolase genes,” J. Biol. Chem., 1981, 256(3), 1385-1395.
Holland et al., “Isolation and identification of yeast messenger ribonucleic acids coding for enolase, glyceraldehyde-3-phosphate dehydrogenase, and phosphoglycerate kinase,” Biochem., 1978, 17(23), 4900-4907.
Houghton, M. et al., “The hepatitis C virus: Genetic organization, persistence, and vaccine strategies,” in Viral Hepatitis and Liver Disease, Nishioka, K. et al. (eds.), Springer-Verlag, Tokyo, 1994, 33-37.
Houghton, M. et al., “Hepatitis C virus: Structure, protein products and processing of the polyprotein precursor”, Curr. Stud. Hematol. Blood Transfus. (Switzerland), 1994, 61, 1-11.
Houghton, M. et al., “Hepatitis delta (.delta.) virus (HDV): Its relationship with introns and plant viroid-like agents and the mapping of immunogenic epitopes within viral polypeptidesȁ
Houghton Michael
Weiner Amy J.
Harbin Alisa A.
Moran Michael J.
Novartis Vaccines and Diagnostics Inc.
Robins Roberta L.
Schwadron Ronald B.
LandOfFree
Conserved motif of hepatitis C virus E2/NS1 region does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conserved motif of hepatitis C virus E2/NS1 region, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conserved motif of hepatitis C virus E2/NS1 region will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3652704